Abstract:The phosphatidylinositol 3-kinase α (PI3Kα) was genetically validated as a promising therapeutic target for developing novel anticancer drugs. In order to explore the structure-activity correlation of benzothiazole series as inhibitors of PI3Kα, comparative molecular field analysis (CoMFA), comparative molecular similarity indices analysis (CoMSIA) were performed on 61 promising molecules to build 3D-QSAR models based on both the ligand- and receptor-based methods. The best CoMFA and CoMSIA models had a cross-validated coefficient r cv 2 of 0.618 and 0.621, predicted correlation coefficient r pred 2 of 0.812 and 0.83, respectively, proving their high correlative and predictive abilities on both the training and test sets. In addition, docking analysis and molecular dynamics simulation (MD) were also applied to elucidate the probable binding modes of these inhibitors at the ATP binding pocket. Based on the contour maps and MD results, some key structural factors responsible for the activity of this series of compounds were revealed as follows: (1) Ring-A has a strong preference for bulky hydrophobic or aromatic groups; (2) Electron-withdrawing groups at the para position of ring-B and hydrophilic substituents in ring-B region may benefit the potency; (3) A polar substituent like -NHSO 2 - between ring-A and ring-B can enhance the activity of the drug by providing hydrogen bonding interaction with the protein target. The satisfactory results obtained from this work strongly suggest that the developed 3D-QSAR models and the obtained PI3Kα inhibitor binding structures are reasonable for the prediction of the activity of new inhibitors and be helpful in future PI3Kα inhibitor design.

Three-dimensional Quantitative Structure-Activity Relationships of Pyrrolopyridinone As Cell Division Cycle Kinase Inhibitors by CoMFA and CoMSIA.

D-QSAR studies on pyrimidine analogues as cyclin-dependent kinase 1 inhibitors

3D-QSAR Study for Inhibitors of Cyclin-Dependent Kinase 4

Pyrrolo[3,2-d]pyrimidine Derivatives As Type II Kinase Insert Domain Receptor (KDR) Inhibitors: CoMFA and CoMSIA Studies

3D-QSAR and 3D-QSSR Studies of Thieno[2,3-D]pyrimidin-4-yl Hydrazone Analogues As CDK4 Inhibitors by CoMFA Analysis

3D-QSAR and Docking Studies on Pyrazolo[4,3-H]qinazoline-3-carboxamides As Cyclin-Dependent Kinase 2 (CDK2) Inhibitors.

Development of in Silico Models for Pyrazoles and Pyrimidine Derivatives As Cyclin-Dependent Kinase 2 Inhibitors

3D-Qsar and Docking Studies on Pyrrolopyrimidine Derivatives As Lim-Kinase 2 Inhibitors

3D-QSAR Study on 2,3-Dihydroimidazo[4,5]-pyridin-2-one Derivatives with a Meta Substitution Pattern As V600E BRAF Inhibitors

Study on the Three-Dimensional Quantitative Structure-Activity Relationship of Pyridazinonyl-Substituted 1,3,4-Thiadiazoles

Three-dimensional Quantitative Structure–activity Relationship Study on Paullones As CDK Inhibitors Using CoMSIA and CoMFA

Three-dimensional quantitative structure–activity relationship study for analogues of TQXs using CoMFA and CoMSIA

Exploring the Structure Requirement for PKCθ Inhibitory Activity of Pyridinecarbonitrile Derivatives: an in Silico Analysis.

Three-Dimensional Quantitative Structure-Activity Relationship of 4,5,6,7-Tetrahydrothienopyridines Analogues As Glucose-6-Phosphatase Inhibitors

Molecular modeling studies on imidazo[4,5-b]pyridine derivatives as Aurora A kinase inhibitors using 3D-QSAR and docking approaches.

Molecular simulation of a series of benzothiazole PI3Kα inhibitors: probing the relationship between structural features, anti-tumor potency and selectivity

Molecular-docking-guided 3D-QSAR Studies of Substituted Isoquinoline-1,3-(2h,4h)-diones As Cyclin-Dependent Kinase 4 (CDK4) Inhibitors.

3d-Qsar Analysis On Pyrrolopyridine Analogs As Mitogen-Activated Protein Kinase-Activated Protein Kinase 2 (Mk-2) Inhibitors

3D-QSAR studies on quinazoline derivatives as EGFR-T790M inhibitors by Comparative Molecular Field Analysis (CoMFA)

3D-QSAR study of pyrrolidine derivatives as matrix metalloproteinase-2 inhibitors

Molecular Docking and 3D-QSAR Studies on Checkpoint Kinase 1 Inhibitors